You are here

  • Home
  • Archive
  • Volume 9, Issue 10
  • Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

https://doi.org/10.1136/jitc-2020-001701corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Ressler JM, Karasek M, Koch L, et al. Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany. J Immunother Cancer 2021;9:e001701. doi: 10.1136/jitc-2020-001701

    This article has been corrected since it first published. The provenance and peer review statement has been added.